Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma.
Kaseb AO, Morris JS, Iwasaki M, Al-Shamsi HO, Raghav KP, Girard L, Cheung S, Nguyen V, Elsayes KM, Xiao L, Abdel-Wahab R, Shalaby AS, Hassan M, Hassabo HM, Wolff RA, Yao JC.
Kaseb AO, et al. Among authors: elsayes km.
Onco Targets Ther. 2016 Feb 15;9:773-80. doi: 10.2147/OTT.S91977. eCollection 2016.
Onco Targets Ther. 2016.
PMID: 26929648
Free PMC article.